Ibogaine is currently unscheduled in Uruguay, meaning it is not explicitly listed as a controlled substance under Uruguayan law, though its legal status exists in a regulatory grey area. Last verified: April 22, 2026.

Current Legal Status

Uruguay does not include ibogaine or iboga (the plant from which it is derived) on its national list of controlled substances. Uruguay's drug scheduling framework is governed primarily by Decree 286/000 and subsequent amendments issued by the Junta Nacional de Drogas (JND), as well as the broader framework established under Law 14.294 (the Ley de Estupefacientes, originally enacted in 1974 and subsequently amended). Neither ibogaine nor Tabernanthe iboga appears on the schedules maintained under these instruments.

Because Uruguay does not have an explicit analogue law comparable to those in the United States or United Kingdom, substances not scheduled are not automatically treated as controlled simply by virtue of pharmacological similarity to a controlled substance. This means that, in practice, ibogaine occupies an unscheduled status — it is neither explicitly legal nor explicitly illegal, but rather falls outside the current scope of drug control legislation.

Uruguay has a notably progressive drug policy tradition. It was the first country in the world to federally regulate recreational cannabis under Law 19.172 (2013), a move that signaled openness to evidence-based drug regulation. This broader policy environment is relevant context for understanding how ibogaine is approached by regulators and health authorities.

The Ministerio de Salud Pública (MSP) regulates medical treatments and pharmaceutical products. Ibogaine is not approved as a pharmaceutical in Uruguay, meaning any clinical use operates outside formal regulatory approval. However, no enforcement actions against ibogaine providers have been publicly documented.

There are no known religious carve-outs or formal exemptions for ibogaine use in Uruguay, nor are there documented ceremonial or indigenous use protections comparable to those governing ayahuasca in Brazil.

Treatment Centers

Uruguay has a small but active community of ibogaine practitioners. Given the unscheduled status of ibogaine, centers and practitioners operate without facing the criminal liability present in countries such as the United States, France, or Belgium. Clinics in Uruguay tend to serve both domestic clients and medical tourists, particularly from the United States and Europe, where ibogaine is controlled.

The quality and formality of ibogaine providers in Uruguay varies considerably — from medically staffed retreat centers to informal practitioner settings. There is no national accreditation framework specifically for ibogaine providers as of 2026.

For a full directory of ibogaine clinics operating in and near Uruguay, visit our clinic directory.

How People Access Ibogaine in Uruguay

Access to ibogaine in Uruguay typically occurs through the following pathways, described here factually and without recommendation:

  • Private treatment centers: A number of retreat-style centers offer ibogaine-assisted treatment, primarily for opioid use disorder and personal development purposes. These centers may or may not employ medical personnel.
  • Independent practitioners: Some individuals access ibogaine through guides or facilitators operating outside a clinical framework. The safety standards in these contexts vary widely.
  • Medical tourism: Foreign nationals travel to Uruguay specifically to access ibogaine, often after being unable to access it legally in their home countries. Uruguay's relatively low cost of living compared to Western Europe makes it an accessible destination.
  • Importation: Because ibogaine is unscheduled, importing it for personal or treatment use does not carry the criminal penalties it would in many other jurisdictions, though customs regulations and international conventions (discussed below) add complexity.

Uruguay is a signatory to the 1971 UN Convention on Psychotropic Substances. Ibogaine is not scheduled under this convention, which means Uruguay's obligations under international drug treaties do not compel it to control ibogaine domestically. This is a key legal distinction that supports ibogaine's continued unscheduled status.

Recent Legal Developments

No legislation specifically targeting ibogaine has been introduced or passed in Uruguay within the past two years. However, several broader developments are relevant:

  • Psychedelic reform discussions: Growing international interest in psilocybin, MDMA, and ibogaine as therapeutic agents has prompted informal discussions within Uruguay's Junta Nacional de Drogas regarding whether emerging psychedelic therapies warrant a formal regulatory framework. No legislative proposals have been tabled as of April 2026.
  • MAPS and global ibogaine advocacy: The global momentum behind ibogaine research — including the landmark randomized controlled trial published in Nature Medicine in 2023 showing ibogaine's efficacy for traumatic brain injury — has increased international visibility of ibogaine as a therapeutic compound. This has indirectly influenced policy conversations in Uruguay.
  • Harm reduction orientation: Uruguay's continued investment in harm reduction policy infrastructure, including robust cannabis regulation and needle exchange programs, suggests the policy environment remains hospitable to evidence-based approaches to psychedelic substances.

Risks of Seeking Treatment in Uruguay

While ibogaine's unscheduled status removes certain legal risks, prospective patients should be aware of the following:

Medical Safety: Ibogaine carries significant cardiac risks, including QT interval prolongation, which can lead to fatal arrhythmias. These risks are present regardless of the legal environment. Reputable providers should conduct pre-screening electrocardiograms (ECGs) and contraindicate ibogaine for individuals with cardiac conditions or those taking certain medications (particularly QT-prolonging drugs and opioids at therapeutic doses).

  • No licensing standards: Uruguay does not have a licensing or accreditation system specific to ibogaine providers. There is no government body that certifies ibogaine practitioners or inspects treatment facilities for ibogaine-specific safety protocols.
  • Variable medical oversight: Some providers operate with licensed medical professionals on staff; others do not. Patients should request documentation of medical supervision and pre-screening protocols before committing to treatment.
  • No consumer protections: In the absence of a regulated pharmaceutical framework, patients have limited legal recourse if treatment causes harm.
  • Purity and sourcing: The ibogaine administered at centers may be sourced internationally. Without pharmaceutical-grade manufacturing standards and third-party testing, purity and dosing accuracy cannot be guaranteed.
  • Return travel: Patients returning to countries where ibogaine is controlled (e.g., the United States, Australia, or EU member states) should be aware that possessing ibogaine for the return journey would be illegal in those jurisdictions. Most reputable centers do not send patients home with ibogaine.
  • Integration support: Post-treatment psychological integration is an important component of outcomes. Patients should confirm what follow-up support, if any, a center provides.

Frequently Asked Questions

Ibogaine is unscheduled in Uruguay — it does not appear on the national list of controlled substances maintained under Law 14.294 and its associated decrees. This means it is not explicitly illegal to possess, use, or administer ibogaine. However, it is also not a licensed pharmaceutical, so any clinical use occurs outside formal regulatory approval. The practical result is a grey area in which ibogaine providers can operate without facing criminal liability, but also without formal regulatory oversight.
Yes. Medical tourism for ibogaine is a documented phenomenon in Uruguay. Foreign nationals are not prohibited from entering Uruguay and receiving ibogaine treatment at a private center. However, individuals should be aware that returning home with ibogaine may be illegal in their country of origin. Additionally, no guarantee of quality or safety exists simply because a center is operating legally under Uruguayan law — due diligence on medical protocols is essential.
Not necessarily. Uruguay's cannabis regulation reflected years of political advocacy, civil society mobilization, and a specific government commitment. As of April 2026, there is no active legislative proposal to formally regulate ibogaine. The current situation — unscheduled and informally tolerated — may persist for some time. Formal regulation could either liberalize access further or introduce new restrictions and standards. It is not possible to predict the direction or timing of any regulatory change.
It depends on the specific provider. Some centers in Uruguay employ licensed physicians and nurses who conduct pre-screening cardiac evaluations, monitor patients during the experience, and are equipped to respond to adverse events. Others operate with minimal or no medical personnel. Because there is no national licensing standard for ibogaine providers, the level of medical supervision varies significantly. Prospective patients should ask explicitly about the qualifications of staff, pre-treatment cardiac screening (ECG), contraindication policies, and emergency protocols before enrolling in any program.
Because ibogaine is not scheduled under Uruguayan law and is not controlled under international drug treaties (it does not appear on UN Convention schedules), importing ibogaine into Uruguay does not face the same legal prohibitions it would in many other countries. However, the country of export may have its own controls — for example, exporting ibogaine from the United States or from EU member states could involve legal issues in the originating country. Customs regulations and documentation requirements may also apply. Anyone considering importation should consult an attorney familiar with both Uruguayan customs law and the law of the country of origin.
Uruguay has a functional public emergency medical system. The national emergency number is 911 for police and medical emergencies. Montevideo and other urban centers have hospitals equipped to handle cardiac emergencies, which are the primary acute risk associated with ibogaine. Because ibogaine is unscheduled, medical professionals can treat patients who have taken ibogaine without the complication of mandatory law enforcement reporting that might arise in countries where ibogaine is controlled. Before beginning treatment, confirm with your provider what their emergency protocols are, whether they have oxygen and defibrillation equipment on site, and how close they are to an emergency medical facility.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.